PACIFIC BIOSCIENCES OF CALIFORNIA, INC. Financials Pacific Biosciences of California, Inc. Börse Stuttgart
Equities
P09
US69404D1081
Advanced Medical Equipment & Technology
|
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1.183 EUR | +7.53% |
|
-18.89% | -88.05% |
| 07-01 | Pacific Biosciences of California, Inc.(NasdaqGS:PACB) dropped from Russell 2500 Growth Index | CI |
| 06-27 | PacBio, Form Bio Team Up to Launch Initiatives to Unify AAV Gene Therapy Industry | MT |
Valuation
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Capitalization 1 | 786.6 | 4,833 | 4,513 | 1,850 | 2,624 | 348.6 | - | - |
| Enterprise Value (EV) 1 | 753.4 | 4,514 | 4,365 | 1,974 | 2,884 | 782.3 | 817.8 | 871.9 |
| P/E ratio | -9.35 x | 153 x | -23 x | -5.84 x | -8.11 x | -1.36 x | -1.78 x | -2.26 x |
| Yield | - | - | - | - | - | - | - | - |
| Capitalization / Revenue | 8.65 x | 61.3 x | 34.6 x | 14.4 x | 13.1 x | 1.94 x | 1.49 x | 1.16 x |
| EV / Revenue | 8.29 x | 57.2 x | 33.4 x | 15.4 x | 14.4 x | 4.35 x | 3.49 x | 2.9 x |
| EV / EBITDA | -8.08 x | -46.1 x | -21.5 x | -6.65 x | -9.16 x | -3.35 x | -4.81 x | -7.48 x |
| EV / FCF | -9.28 x | 244 x | -37.3 x | -7.05 x | -10.8 x | -3.71 x | -5.83 x | -9.28 x |
| FCF Yield | -10.8% | 0.41% | -2.68% | -14.2% | -9.29% | -27% | -17.1% | -10.8% |
| Price to Book | 14.3 x | 12.8 x | 5.72 x | 3.29 x | 3.75 x | 0.65 x | 0.71 x | 0.78 x |
| Nbr of stocks (in thousands) | 153,034 | 186,309 | 220,598 | 226,109 | 267,444 | 272,356 | - | - |
| Reference price 2 | 5.140 | 25.94 | 20.46 | 8.180 | 9.810 | 1.280 | 1.280 | 1.280 |
| Announcement Date | 06/02/20 | 10/02/21 | 15/02/22 | 16/02/23 | 15/02/24 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 90.89 | 78.89 | 130.5 | 128.3 | 200.5 | 179.8 | 234.4 | 300.6 |
| EBITDA 1 | -93.28 | -97.96 | -202.9 | -296.8 | -314.7 | -233.4 | -170.2 | -116.5 |
| EBIT 1 | -100.5 | -104.4 | -210.4 | -307.2 | -334.5 | -258.6 | -201.4 | -160.6 |
| Operating Margin | -110.62% | -132.31% | -161.24% | -239.43% | -166.8% | -143.82% | -85.92% | -53.42% |
| Earnings before Tax (EBT) 1 | -84.13 | 29.4 | -274.9 | -314.2 | -318.2 | -253.3 | -201.9 | -162.7 |
| Net income 1 | -84.13 | 29.4 | -181.2 | -314.2 | -306.7 | -254.9 | -202.2 | -162.7 |
| Net margin | -92.57% | 37.27% | -138.85% | -244.92% | -152.97% | -141.78% | -86.28% | -54.13% |
| EPS 2 | -0.5500 | 0.1700 | -0.8900 | -1.400 | -1.210 | -0.9389 | -0.7200 | -0.5662 |
| Free Cash Flow 1 | -81.15 | 18.46 | -117.1 | -280 | -268 | -211.1 | -140.2 | -94 |
| FCF margin | -89.28% | 23.4% | -89.73% | -218.2% | -133.66% | -117.41% | -59.82% | -31.27% |
| FCF Conversion (EBITDA) | - | - | - | - | - | - | - | - |
| FCF Conversion (Net income) | - | 62.8% | - | - | - | - | - | - |
| Dividend per Share 2 | - | - | - | - | - | - | - | - |
| Announcement Date | 06/02/20 | 10/02/21 | 15/02/22 | 16/02/23 | 15/02/24 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: December | 2021 Q4 | 2022 Q1 | 2022 Q2 | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 | 2025 Q1 | 2025 Q2 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 36.02 | 33.17 | 35.47 | 32.31 | 27.35 | 38.9 | 47.57 | 55.69 | 58.36 | 38.81 | 41.31 | 46.3 | 52.37 | 49.54 | 54.35 |
| EBITDA 1 | -62.19 | -75.03 | -65.42 | -72.04 | -84.31 | -88.26 | -71.12 | -68.2 | -77.72 | -71.27 | -62.26 | -52 | -44.84 | -45.7 | -48.3 |
| EBIT 1 | -64.68 | -77.52 | -67.97 | -74.62 | -87.08 | -91.25 | -73.18 | -73.04 | -87.55 | -81.36 | -67.1 | -58.79 | -52.82 | -54.78 | -56.04 |
| Operating Margin | -179.56% | -233.69% | -191.64% | -230.94% | -318.37% | -234.58% | -153.82% | -131.16% | -150.02% | -209.64% | -162.43% | -126.97% | -100.86% | -110.58% | -103.12% |
| Earnings before Tax (EBT) 1 | -68.15 | -81.5 | -71.39 | -76.97 | -84.38 | -88.02 | -69.83 | -77.58 | -82.74 | -78.18 | -66.35 | -59.21 | -52.3 | -58.92 | -57.18 |
| Net income 1 | -69.33 | -81.5 | -71.39 | -76.97 | -84.38 | -88.02 | -69.83 | -66.87 | -82.02 | -78.18 | -66.35 | -59.21 | -52.3 | -58.92 | -57.18 |
| Net margin | -192.48% | -245.68% | -201.3% | -238.22% | -308.5% | -226.26% | -146.79% | -120.07% | -140.55% | -201.44% | -160.62% | -127.87% | -99.88% | -118.93% | -105.2% |
| EPS 2 | -0.3100 | -0.3700 | -0.3200 | -0.3400 | -0.3700 | -0.3600 | -0.2800 | -0.2600 | -0.3100 | -0.2900 | -0.2375 | -0.2125 | -0.1862 | -0.1975 | -0.1925 |
| Dividend per Share | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Announcement Date | 15/02/22 | 04/05/22 | 03/08/22 | 07/11/22 | 16/02/23 | 02/05/23 | 02/08/23 | 30/10/23 | 15/02/24 | 09/05/24 | - | - | - | - | - |
1USD in Million2USD
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net Debt 1 | - | - | - | 124 | 261 | 434 | 469 | 523 |
| Net Cash position 1 | 33.2 | 319 | 148 | - | - | - | - | - |
| Leverage (Debt/EBITDA) | - | - | - | -0.419 x | -0.8287 x | -1.858 x | -2.758 x | -4.491 x |
| Free Cash Flow 1 | -81.1 | 18.5 | -117 | -280 | -268 | -211 | -140 | -94 |
| ROE (net income / shareholders' equity) | -99.6% | 7.53% | -33.7% | -46.4% | -48.5% | -37.7% | -35.4% | -23.3% |
| ROA (Net income/ Total Assets) | -52.9% | 5.23% | -15.7% | -16.5% | -17.5% | -14% | -12.7% | - |
| Assets 1 | 159.1 | 562 | 1,154 | 1,907 | 1,757 | 1,819 | 1,595 | - |
| Book Value Per Share 2 | 0.3600 | 2.030 | 3.580 | 2.490 | 2.620 | 1.980 | 1.800 | 1.640 |
| Cash Flow per Share | - | - | - | - | - | - | - | - |
| Capex 1 | 2.84 | 1.04 | 5.93 | 16.8 | 8.84 | 9.2 | 10.9 | 12.7 |
| Capex / Sales | 3.12% | 1.32% | 4.54% | 13.05% | 4.41% | 5.12% | 4.65% | 4.21% |
| Announcement Date | 06/02/20 | 10/02/21 | 15/02/22 | 16/02/23 | 15/02/24 | - | - | - |
1USD in Million2USD
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Year-on-year evolution of the Yield
Change in Enterprise Value/EBITDA
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
14
Last Close Price
1.28
USD
Average target price
4.25
USD
Spread / Average Target
+232.03%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +0.59% | 204B | |
| +3.92% | 178B | |
| +30.07% | 156B | |
| +32.42% | 113B | |
| +1.71% | 64.26B | |
| +19.65% | 54.98B | |
| -1.86% | 47.44B | |
| -9.53% | 36.7B | |
| -1.28% | 34.84B |
- Stock Market
- Equities
- PACB Stock
- P09 Stock
- Financials Pacific Biosciences of California, Inc.
